MedTrace Logo

Rapamycin Plus Bevacizumab in Advanced Cancers

NCT00667485 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2014-01-17

No results posted yet for this study

Summary

The goal of this trial is to determine the toxicity and maximum dose of rapamycin and bevacizumab given together to subjects with advanced cancers. This study will also look at the pharmacokinetics and antitumor activity of the combination.

Conditions

Interventions

DRUG

Rapamycin (liquid)

Weekly Rapamycin (liquid) 90mg (dose will be split 45mg on Day 1 and Day 2 of each week)

DRUG

Bevacizumab

Multiple doses (dose depends on time of study entry) given by IV once every 3 weeks

DRUG

Rapamycin (Tablets)

Daily oral rapamycin (tablets) - 2 doses will be tested 4mg and 6mg

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • University of Chicago

    lead OTHER

Principal Investigators

  • Ezra Cohen, MD · University of Chicago

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2012-05-31
Completion
2012-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00667485 on ClinicalTrials.gov